Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

anti-CD38 monoclonal antibody SAR442085

A preparation of Fc-engineered monoclonal antibody that targets the cell surface glycoprotein CD-38 with potential antineoplastic activity. Although the exact mechanisms(s) through which this agent exerts its effects have yet to be fully elucidated, upon administration, anti-CD38 monoclonal antibody SAR442085 targets and binds to CD38 on CD38-positive tumor cells. This may trigger, in addition to other possible responses, antitumoral antibody-dependent cellular cytotoxicity (ADCC) and may eventually lead to cell lysis in CD38-expressing tumor cells. CD38, a type II transmembrane glycoprotein, is present on various immune cells and hematologic malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Code name:SAR 442085
SAR-442085
SAR442085
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search